- Home
- PHIO vs LYRA Comparison
PHIO vs LYRA Comparison
Compare PHIO & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- LYRA
- Stock Information
- Founded
- PHIO 2011
- LYRA 2005
- Country
- PHIO United States
- LYRA United States
- Employees
- PHIO N/A
- LYRA N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- LYRA Medical/Dental Instruments
- Sector
- PHIO Health Care
- LYRA Health Care
- Exchange
- PHIO Nasdaq
- LYRA Nasdaq
- Market Cap
- PHIO 13.7M
- LYRA 11.3M
- IPO Year
- PHIO N/A
- LYRA 2020
- Fundamental
- Price
- PHIO $2.31
- LYRA $7.51
- Analyst Decision
- PHIO Strong Buy
- LYRA Hold
- Analyst Count
- PHIO 3
- LYRA 1
- Target Price
- PHIO $10.67
- LYRA $16.00
- AVG Volume (30 Days)
- PHIO 161.3K
- LYRA 27.2K
- Earning Date
- PHIO 11-13-2025
- LYRA 11-11-2025
- Dividend Yield
- PHIO N/A
- LYRA N/A
- EPS Growth
- PHIO N/A
- LYRA N/A
- EPS
- PHIO N/A
- LYRA N/A
- Revenue
- PHIO N/A
- LYRA $770,000.00
- Revenue This Year
- PHIO N/A
- LYRA N/A
- Revenue Next Year
- PHIO N/A
- LYRA $123.83
- P/E Ratio
- PHIO N/A
- LYRA N/A
- Revenue Growth
- PHIO N/A
- LYRA N/A
- 52 Week Low
- PHIO $0.97
- LYRA $3.81
- 52 Week High
- PHIO $9.79
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- PHIO 54.93
- LYRA 60.49
- Support Level
- PHIO $2.28
- LYRA $6.55
- Resistance Level
- PHIO $2.45
- LYRA $8.75
- Average True Range (ATR)
- PHIO 0.12
- LYRA 0.56
- MACD
- PHIO 0.02
- LYRA 0.19
- Stochastic Oscillator
- PHIO 54.72
- LYRA 57.65
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.